The JAK2 46/1 Haplotype: a Marker of Inappropriate Myelomonocytic Response to Cytokine Stimulation, Leading to Increased Risk of Inflammation, Myeloid Neoplasm, and Impaired Defense Against Infection?

Overview

Journal Haematologica

Specialty Hematology

Date 2011 Nov 8

PMID 22058280

Citations 37

Authors

Sylvie Hermouet

Mathias Vilaine

Affiliations

Soon will be listed here.

Citing Articles

Journey to diagnosis: An unfinished exploration of IgG4-related sclerosing cholangitis.

Liang M, Chen Y, He Y, He Y World J Clin Cases. 2024; 12(33):6608-6612.

PMID: 39600477 PMC: 11514334. DOI: 10.12998/wjcc.v12.i33.6608.

Wu Z, Ji R, Xiao Y, Wang Y, Zhao C World J Clin Cases. 2024; 12(24):5589-5595.

PMID: 39188618 PMC: 11269987. DOI: 10.12998/wjcc.v12.i24.5589.

Association between the polymorphism and the risk of hematologic malignancies: data from a meta-analysis.

Alves-Hanna F, Silva F, Pereira D, Leal A, Magalhaes-Gama F, Costa A Cancer Biol Ther. 2024; 25(1):2382503.

PMID: 39039694 PMC: 11268255. DOI: 10.1080/15384047.2024.2382503.

Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.

Paes J, Torres D, Aquino D, Alves E, Mesquita E, Sousa M Sci Rep. 2024; 14(1):9389.

PMID: 38654055 PMC: 11039700. DOI: 10.1038/s41598-024-60090-x.

Portal Vein Thrombosis: State-of-the-Art Review.

Boccatonda A, Gentilini S, Zanata E, Simion C, Serra C, Simioni P J Clin Med. 2024; 13(5).

PMID: 38592411 PMC: 10932352. DOI: 10.3390/jcm13051517.

References

Corre-Buscail I, Pineau D, Boissinot M, Hermouet S . Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8. Exp Hematol. 2005; 33(11):1299-308. DOI: 10.1016/j.exphem.2005.07.002. View

Tiedt R, Hao-Shen H, Sobas M, Looser R, Dirnhofer S, Schwaller J . Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2007; 111(8):3931-40. DOI: 10.1182/blood-2007-08-107748. View

Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G . JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010; 24(10):1809-13. DOI: 10.1038/leu.2010.172. View

Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I . A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009; 41(4):450-4. DOI: 10.1038/ng.341. View

Pardanani A, Fridley B, Lasho T, Gilliland D, Tefferi A . Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2007; 111(5):2785-9. DOI: 10.1182/blood-2007-06-095703. View

Jones A, Campbell P, Beer P, Schnittger S, Vannucchi A, Zoi K . The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010; 115(22):4517-23. PMC: 3145114. DOI: 10.1182/blood-2009-08-236448. View

Kilpivaara O, Mukherjee S, Schram A, Wadleigh M, Mullally A, Ebert B . A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009; 41(4):455-9. PMC: 3676425. DOI: 10.1038/ng.342. View

Smalberg J, Koehler E, Murad S, Plessier A, Seijo S, Trebicka J . The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011; 117(15):3968-73. DOI: 10.1182/blood-2010-11-319087. View

Tefferi A, Lasho T, Patnaik M, Finke C, Hussein K, Hogan W . JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2009; 24(1):105-9. DOI: 10.1038/leu.2009.225. View

10.

Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau J . JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia. 2010; 24(5):1069-73. DOI: 10.1038/leu.2010.23. View

11.

Brandt B, Kemming D, Packeisen J, Simon R, Helms M, Feldmann U . Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Endocr Relat Cancer. 2005; 12(4):823-37. DOI: 10.1677/erc.1.00975. View

12.

Kouroupi E, Kiladjian J, Chomienne C, Dosquet C, Bellucci S, Valla D . The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood. 2011; 117(21):5777-8. DOI: 10.1182/blood-2011-03-343657. View

13.

Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S . Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. Oncogene. 2010; 30(8):990-1001. DOI: 10.1038/onc.2010.479. View

14.

Qi X, Shao M, Peng H, Bi Z, Su Z, Li H . In vitro differentiation of bone marrow stromal cells into neurons and glial cells and differential protein expression in a two-compartment bone marrow stromal cell/neuron co-culture system. J Clin Neurosci. 2010; 17(7):908-13. DOI: 10.1016/j.jocn.2009.10.013. View

15.

Barrett J, Hansoul S, Nicolae D, Cho J, Duerr R, Rioux J . Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40(8):955-62. PMC: 2574810. DOI: 10.1038/ng.175. View

16.

Ferguson L, Han D, Fraser A, Huebner C, Lam W, Morgan A . Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res. 2010; 690(1-2):108-15. DOI: 10.1016/j.mrfmmm.2010.01.017. View

17.

Barbui T, Carobbio A, Finazzi G, Vannucchi A, Barosi G, Antonioli E . Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2010; 96(2):315-8. PMC: 3031701. DOI: 10.3324/haematol.2010.031070. View

18.

Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Tiab M, Ramee J . Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood. 2011; 118(24):6468-70. DOI: 10.1182/blood-2011-08-372813. View

19.

Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V . The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006; 108(6):1865-7. DOI: 10.1182/blood-2006-01-013540. View

20.

Nahajevszky S, Andrikovics H, Batai A, Adam E, Bors A, Csomor J . The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Haematologica. 2011; 96(11):1613-8. PMC: 3208678. DOI: 10.3324/haematol.2011.043885. View